<DOC>
	<DOCNO>NCT02844777</DOCNO>
	<brief_summary>This Phase 2 clinical trial multi-center , randomize , double-blind , placebo-controlled , multiple-dose , parallel-cohort study ass efficacy , safety tolerability VDA-1102 treatment actinic keratosis ( AK ) head male female adult subject .</brief_summary>
	<brief_title>Efficacy Safety VDA-1102 Ointment Treatment Actinic Keratosis</brief_title>
	<detailed_description>Approximately 84 subject meet study 's enrollment criterion completion Screening Period randomize receive 5 % 10 % VDA-1102 , matched-placebo . During Treatment Period , study drug apply once-daily 28 day 25 square centimeter area skin contain 4-8 actinic keratosis lesion face scalp . Subjects follow additional 28 day ( Observation Period ) wherein study drug apply . The purpose study determine whether once-daily application VDA-1102 ointment 28 day effective well-tolerated treatment actinic keratosis face scalp .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Main Subject minimum 4 maximum 8 discrete Grade 12 AK lesion within single 25 square centimeter area skin scalp face Main Subject : ( ) pregnant ; ( b ) lactating ; ( c ) planning become pregnant study , ( ) fertile fertile partner unable unwilling use require contraceptive method Subject immunosuppressed Subject use follow topical treatment Treatment Field : ( 1 ) topical retinoids within 8 week Screening ( 2 ) microdermabrasion , laser ablative treatment , ALAPDT , chemical peel , 5FU , diclofenac , imiquimod , ingenol , topical treatment AK might impact AK within 12 week Screening . Subject use systemic retinoid therapy within 6 month Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>topical ointment</keyword>
	<keyword>skin</keyword>
	<keyword>hexokinase</keyword>
	<keyword>precancerous condition</keyword>
	<keyword>carcinoma , squamous cell</keyword>
</DOC>